Vancouver, British Columbia--(Newsfile Corp. - February 26, 2026) - Masivo Silver Corp. (TSXV: MASS) (OTC Pink: GNYPF) (FSE: R74) ("Masivo" or the "Company") is pleased to announce that the Company's Phase I diamond drill program has begun at its Cerro Colorado Project in Sonora, Mexico.The initial phase of the program consists of approximately eight (8) diamond drill holes totaling an estimated 1,500 to 2,000 meters. The program is designed to systematically test high-priority silver-copper targets identi ...

Core Insights - 908 Devices Inc. shares experienced a significant increase of 19.2% to $6.52, following a strong trading volume, contrasting with a 7.8% decline over the previous four weeks [1][2] Financial Performance - The company reported preliminary unaudited financial results for Q4 2025, with revenue reaching $17.2 million, indicating a growth of approximately 20%. This growth was attributed to strong performance in the U.S. state and local channel, increased international adoption of VipIR, and sales to federal and defense customers [2] - The company achieved a positive adjusted EBITDA in the fourth quarter, reflecting operational efficiency [2] Earnings Expectations - For the upcoming report, 908 Devices is expected to post a quarterly loss of $0.06 per share, which represents a year-over-year change of +81.3%. Revenue is anticipated to be $15.84 million, down 15.8% from the same quarter last year [3] - The consensus EPS estimate for the quarter has remained unchanged over the last 30 days, indicating stability in earnings expectations [4] Industry Context - 908 Devices is part of the Zacks Medical - Instruments industry, where another company, Sight Sciences, Inc., saw a decline of 3.6% in its last trading session and has returned -23.3% over the past month [4] - Sight Sciences' consensus EPS estimate for the upcoming report has also remained unchanged, reflecting a year-over-year change of +26.1% [5]

Financial Results - 908 Devices announced preliminary financial results for Q4 and fiscal year 2025 on January 20, 2026[4]. - The financial results will be detailed in a press release, which is included as Exhibit 99.1[4]. - The report is not deemed "filed" under the Securities Exchange Act of 1934, indicating it is preliminary information[5]. - No specific financial metrics or performance indicators were disclosed in the provided documents[4]. Company Information - The company is listed on the NASDAQ Global Market under the trading symbol MASS[2]. - The company has not indicated whether it is an emerging growth company[3].

Core Viewpoint - Masivo Silver Corp. is set to significantly ramp up operations at its Cerro Colorado Project in Sonora, Mexico, with preparations for a 1500 meters Phase I drill program underway [1][2]. Project Advancement Highlights and Ongoing Field Activities - The Phase I drill program aims to test priority targets identified through surface sampling, geological mapping, and historical data review, focusing on areas with strong potential for silver discovery [4]. - Current activities include rehabilitation of access routes, construction of drill pads, and site preparation necessary for drilling [2][11]. Historical Sampling Highlights and Geological Context - Historical records indicate high-grade silver and gold values from underground workings, with a notable sample from 1972 showing 2,200 g/t silver and 4.57 g/t gold [5]. - Another historical sample returned values of 1,840 g/t silver, 4.8 g/t gold, 3.06% copper, 4.5% lead, and 2.92% zinc [6]. - These historical samples, while selective, provide geological context and support the presence of a multi-metal mineralizing system [7]. Management Commentary - The President and CEO of Masivo Silver Corp. expressed excitement about launching the maiden drill program, emphasizing the geological potential based on historical sampling [8]. - The Senior Geologist highlighted the productive nature of the mineral system at Cerro Colorado, reinforcing confidence in the upcoming drill program [9]. Technical Oversight - The Phase I drill program will be supervised by experienced geologists, ensuring adherence to technical standards [12]. Stock Option Grant - The company has granted 2,550,000 stock options to directors, officers, and consultants, exercisable at $0.085 per share for five years [13]. Company Overview - Masivo Silver Corp. is a Canadian junior exploration company focused on gold, silver, copper, and base metal projects in Mexico and Nevada, with current projects including the Cerro Colorado Property and the Boston Mine Project [14].

Core Viewpoint - Masivo Silver Corp. is advancing its Cerro Colorado Project in Sonora, Mexico, with significant progress in permitting and plans to commence drilling in January 2026 [1][4][6]. Permitting Progress - The company has submitted environmental permit applications to SEMARNAT for exploration activities, including drilling and infrastructure preparation [2]. - This submission is a key milestone that demonstrates the company's commitment to regulatory compliance in Mexico [3]. Planned Phase 1 Drill Program - The Phase 1 drill program is targeted to start in January 2026, pending necessary regulatory approvals [4]. - The program aims to confirm known mineralization and expand zones of interest for precious and base metals [5]. Management Commentary - The CEO of Masivo Silver Corp. highlighted the significance of the SEMARNAT permit submission as a step forward for the project, emphasizing efficient movement into drilling [6]. Project Advancement and Strategy - Cerro Colorado is a cornerstone asset in Masivo's portfolio, with a focus on regulatory compliance, community relationships, and technical rigor [7].

Summary of 908 Devices FY Conference Call Company Overview - **Company**: 908 Devices (NasdaqGM:MASS) - **Focus**: Transitioned from a broad instrumentation provider to a company focused on handheld chemical detection for public health, safety, and defense through a transformation called "908 2.0" [2][6] Key Points Transformation and Business Focus - The transformation is complete, with a focus on growth markets, specifically handheld chemical detection [3] - Divested the desktop business to sharpen focus on handheld markets, which are seeing increased demand due to macro trends like the opioid crisis and defense modernization [3][4] - The company aims for 13%-17% growth this year, accelerating to over 20% next year on the product side [3] Financial Performance - Year-to-date revenue growth of 16% driven by new product launches [10] - Gross margins improved to 56% year-to-date, reaching 58% in Q3 due to operational streamlining and manufacturing consolidation [11] - Adjusted EBITDA loss improved by 32% year-over-year and 53% quarter-over-quarter [4] - Projected revenue for the full year is between $54 million and $56 million, with a goal of achieving positive adjusted EBITDA in Q4 [12] Product Development and Market Strategy - Expanded product portfolio from one handheld device to five, with more in development [5][9] - New handheld analyzer, Viper, launched in Q3, combining FTIR and Raman technologies for enhanced chemical identification [17][20] - Explorer device has seen strong sales, with a 30% quarter-over-quarter growth and significant adoption among first responders [23][24] Growth Catalysts for 2026 - Key growth drivers identified as equipment modernization, the NextGen MX908 launch, and the DOD AFCAD program [32][33] - The company expects to leverage a legacy base of over 15,000 products for upgrades, with a focus on innovative solutions [33] - Anticipated revenue from the AFCAD program could exceed $10 million when fully ramped [36] Market Opportunities - Strong traction in state and local government markets, driven by funding opportunities and the need for advanced chemical detection due to the opioid crisis [30][31] - International expansion opportunities identified, particularly in the Middle East and potential growth in APAC [11][30] Recurring Revenue Strategy - Approximately one-third of revenue comes from service and support contracts, with plans to enhance connected services through the Team Leader software application [25][26][27] Cash Position and Investment Strategy - Strong cash position of $112 million with no debt, allowing flexibility for organic and potential inorganic investments [37][38] Additional Insights - The company is focused on maintaining a simplified operational model while pursuing high-impact markets [6] - The transformation is seen as a pivotal shift, positioning the company for long-term growth and profitability [2][6]

Group 1 - The article does not provide any specific content related to a company or industry [1]

Summary of 908 Devices Conference Call Company Overview - **Company**: 908 Devices (NasdaqGM:MASS) - **Industry**: Life Sciences and Diagnostics Key Financial Highlights - **Q3 Revenue**: $14 million, exceeding consensus of $13.5 million [3][4] - **Guidance**: Maintained revenue guidance of $54 million to $56 million for Q4 [25] - **Cash Position**: Ended the quarter with $112 million in cash [5] Business Transformation - **Acquisition**: Acquired RedWave, enhancing handheld product portfolio from 1 to 5 products [5][6] - **Divestiture**: Sold PAT business to Repligen, generating approximately $70 million [5] - **Cost Structure**: Consolidated manufacturing to Danbury, Connecticut, leading to a lower cost footprint [6] Product Development and Market Focus - **Product Launches**: Continued launch of Viper product and Explorer, with record performance [4][8] - **Market Segments**: Focus on drug detection (e.g., fentanyl crisis) and toxic materials [6][30] - **Government Partnerships**: Collaboration with Smith's Detection for the Avcad program targeting military applications [11][12] Revenue Streams and Diversification - **Revenue Sources**: 47% from state and local channels, 25% from international channels [28] - **Fentanyl Detection**: Majority of revenues driven by fentanyl and drug detection capabilities [36][37] Challenges and Risks - **Government Shutdown Impact**: Approximately $4 million in revenue tied up due to government shutdown, affecting Q4 revenue recognition [24][25] - **Export Licensing Delays**: $1 million to $3 million in international orders pending export license approval [26] Future Growth Catalysts - **Next-Gen Products**: Anticipated launch of next-generation MX908, expected to enhance market position [40][42] - **Enterprise Accounts**: Potential for enterprise-level deals with Viper and Explorer products [55][56] - **Long-Term Growth**: Projected 20% product growth in 2026, with opportunities for further expansion in 2027 and beyond [75] Operational Insights - **Production Capacity**: Confident in production capabilities to meet demand, with plans to ramp up labor as needed [19][20] - **Partnerships**: Emphasizing strategic partnerships to enhance market reach and product integration [70][71] Profitability Outlook - **Adjusted EBITDA**: Expected positive adjusted EBITDA in Q4, with a target of $16 million [73] - **Sustained Profitability**: Anticipated crossover into consistent profitability in the future, though 2026 may not be the year for sustained positive results [74] Conclusion - **Overall Sentiment**: Positive outlook on business transformation, product innovation, and market opportunities, despite short-term challenges related to government operations and export licensing delays [76][78]

Core Insights - 908 Devices Inc. (NASDAQ:MASS) is focused on handheld chemical analysis tools for health, safety, and defense applications, aiming to establish a more predictable and profitable business model through its 908 Devices 2.0 vision [1] Financial Performance - For Q3 2025, MASS reported an earnings per share (EPS) of -$0.41, missing the estimated EPS of -$0.11 and significantly below the Zacks Consensus Estimate of a $0.13 loss [2][6] - The company exceeded revenue expectations with $14 million in revenue, surpassing the estimated $13.5 million and the Zacks Consensus Estimate by 3.17%, although this represents a decline from $16.77 million reported a year ago [3][6] - MASS has a negative price-to-earnings (P/E) ratio of approximately -12.42, indicating current losses, while the price-to-sales ratio is about 3.81, suggesting investors are willing to pay $3.81 for every dollar of sales [4] - The enterprise value to sales ratio is approximately 2.87, providing insight into the company's valuation relative to its revenue [4] Financial Health - The company maintains a strong current ratio of approximately 4.98, indicating good short-term financial health and liquidity [5][6] - MASS has a low debt-to-equity ratio of about 0.03, showing minimal reliance on debt financing [5] - The enterprise value to operating cash flow ratio is negative at around -6.04, highlighting potential challenges in generating cash flow from operations [5]

Financial Data and Key Metrics Changes - Revenue from continuing operations was $14 million, down 4% year over year but up 8% sequentially, driven by strong demand for FTIR devices [4][18] - Year-to-date revenues from continuing operations totaled $38.8 million, representing a 16% increase year over year [5] - Adjusted EBITDA loss was $1.8 million for Q3, an improvement of over $5 million year over year [5][22] - The company ended the quarter with approximately $112 million in cash and marketable securities, with no debt outstanding [23] Business Line Data and Key Metrics Changes - FTIR devices accounted for 42% of revenue, with the Explorer Gas Identification device showing strong demand [4] - Recurring revenue represented 36% of total revenue, with a 10% increase year over year [5][19] - Handheld product and service revenue was $13.2 million, down 5% from the prior year [18] Market Data and Key Metrics Changes - The U.S. Coast Guard purchased 23 MX908 devices for narcotics interdiction, contributing to the installed base growth of 27% year over year [4] - International engagement and order flow remain solid, although U.S. export licensing requirements may extend delivery times [7] Company Strategy and Development Direction - The company aims to increase adoption of its devices to address global threats to public health and safety, focusing on rapid chemical identification tools [8][9] - The strategy includes expanding the handheld portfolio and increasing the share of recurring revenue to reduce dependency on large enterprise deals [26] - The company is also advancing its next-gen analytical tools portfolio, including the launch of VIPER, a handheld chemical analyzer [12][15] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about achieving full-year guidance despite potential impacts from the U.S. government shutdown [8][24] - The company expects revenue from continuing operations to be in the range of $54-$56 million for the full year, representing growth of 13%-17% over 2024 [23][24] - Management highlighted the importance of government resuming normal operations for achieving Q4 revenue expectations [30] Other Important Information - The company is on track to achieve positive adjusted EBITDA by Q4 2025, supported by revenue projections and lower operating costs [26] - The gross margin increased to 58% on an adjusted basis, reflecting improvements from operational changes [16][21] Q&A Session Summary Question: Clarification on the $4 million impact on guidance - Management confirmed that the $4 million potential impact is included in the full-year guidance and is considered a timing issue [29][30] Question: Update on AVCAD program and Coast Guard order - The Coast Guard order was included in Q3 shipments, and clarity on the AVCAD program's next steps is expected by year-end [31][32] Question: Sensitivities around adjusted EBITDA break-even - Management indicated that achieving adjusted EBITDA positivity is contingent on landing anticipated orders and maintaining revenue guidance [34][36] Question: Production capabilities and supply chain risks - Management expressed confidence in production capabilities and does not foresee significant supply chain issues affecting AVCAD fulfillment [45][46] Question: Impact of government shutdown on future revenues - Management views the shutdown as a timing issue and remains optimistic about the pipeline and future revenue recognition [47][50]